Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Author(s) -
Kim A. Connelly,
C. David Mazer,
Pankaj Puar,
Hwee Teoh,
ChaoHung Wang,
Tamique Mason,
Farhad Akhavein,
ChingWen Chang,
MinHui Liu,
NingI Yang,
Wei-Siang Chen,
YuHsiang Juan,
Erika Opingari,
Yaseen Salyani,
William Barbour,
Aryan Pasricha,
Shamon Ahmed,
Andrew Kosmopoulos,
Raj Verma,
Michael Moroney,
Ehab Bakbak,
Aishwarya Krishnaraj,
Deepak L. Bhatt,
Javed Butler,
Mikhail Kosiborod,
Carolyn S.P. Lam,
David A. Hess,
Otávio R. CoelhoFilho,
Myriam LafrenièreRoula,
Kevin E. Thorpe,
Adrian Quan,
Lawrence A. Leiter,
Andrew T. Yan,
Subodh Verma
Publication year - 2022
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.122.062769
Subject(s) - empagliflozin , medicine , heart failure , cardiology , ejection fraction , diabetes mellitus , placebo , interquartile range , type 2 diabetes , endocrinology , alternative medicine , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom